Anavex Life Sciences Corp. 0HFR.L Stock
Anavex Life Sciences Corp. Price Chart
Anavex Life Sciences Corp. 0HFR.L Financial and Trading Overview
Anavex Life Sciences Corp. stock price | 4.3 USD |
Previous Close | 6.61 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 14.8 USD |
Volume | 13.26K USD |
Avg. Volume | 3.07K USD |
Market Cap | 354.9M USD |
Beta (5Y Monthly) | 0.683609 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.579 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0HFR.L Valuation Measures
Enterprise Value | 350.88M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 3.4224627 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | N/A |
Trading Information
Anavex Life Sciences Corp. Stock Price History
Beta (5Y Monthly) | 0.683609 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 14.8 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 7.82 USD |
200-Day Moving Average | 9.09 USD |
0HFR.L Share Statistics
Avg. Volume (3 month) | 3.07K USD |
Avg. Daily Volume (10-Days) | 2.16K USD |
Shares Outstanding | 45.43M |
Float | 79.36M |
Short Ratio | N/A |
% Held by Insiders | 3.19% |
% Held by Institutions | 33.90% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | September 30, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | September 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -21.75% |
Return on Equity (ttm) | -34.72% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | N/A |
Net Income Avi to Common (ttm) | -51649372 USD |
Diluted EPS (ttm) | -0.579 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 154.82M USD |
Total Cash Per Share (mrq) | 1.89 USD |
Total Debt (mrq) | 0 USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 14.275 |
Book Value Per Share (mrq) | 1.803 |
Cash Flow Statement
Operating Cash Flow (ttm) | -25979306 USD |
Levered Free Cash Flow (ttm) | -9765258 USD |
Profile of Anavex Life Sciences Corp.
Country | United Kingdom |
State | NY |
City | New York |
Address | 630 5th Avenue |
ZIP | 10111 |
Phone | 844 689 3939 |
Website | https://www.anavex.com |
Industry | |
Sector(s) | |
Full Time Employees | 38 |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Q&A For Anavex Life Sciences Corp. Stock
What is a current 0HFR.L stock price?
Anavex Life Sciences Corp. 0HFR.L stock price today per share is 4.3 USD.
How to purchase Anavex Life Sciences Corp. stock?
You can buy 0HFR.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Anavex Life Sciences Corp.?
The stock symbol or ticker of Anavex Life Sciences Corp. is 0HFR.L.
How many shares does Anavex Life Sciences Corp. have in circulation?
The max supply of Anavex Life Sciences Corp. shares is 575.13K.
What is Anavex Life Sciences Corp. Price to Earnings Ratio (PE Ratio)?
Anavex Life Sciences Corp. PE Ratio is now.
What was Anavex Life Sciences Corp. earnings per share over the trailing 12 months (TTM)?
Anavex Life Sciences Corp. EPS is -0.579 USD over the trailing 12 months.